基于FLAIR MRI生物标志物在痴呆队列中的脑年龄估计
本研究基于3239例FLAIR MR脑容积训练机器学习模型预测正常对照年龄,计算脑年龄差距(BrainAGE)作为生物标志物。BrainAGE在稳定型轻度认知障碍与转化型轻度认知障碍组间横断面和纵向分析中均有显著差异,转化前4年即可检出差异,且与已建立的阿尔茨海默病转化生物标志物显著相关。
要点
- BrainAGE由FLAIR MRI的容积、强度和纹理特征计算,模型在留出正常对照数据上平均绝对误差为2.46年。
- 稳定型轻度认知障碍与转化型轻度认知障碍组的BrainAGE在横断面和纵向分析中均有显著差异,转化前4年即可检出。
- BrainAGE与已建立的阿尔茨海默病转化生物标志物显著相关,可作为单一可解释值总结多维疾病信息。
核心结论
- BrainAGE指标可让临床医生考虑使用一个单一可解释值来总结所有生物标志物,因为它考虑疾病的多个维度,并能用单一值判断受试者是否呈正常衰老模式或趋向高风险类别。
研究设计与样本
- 机器学习模型基于3239例FLAIR MR脑容积的容积、强度和纹理特征训练,用于预测正常对照受试者年龄;BrainAGE为预测年龄与真实年龄之差,用于横断面和纵向分析;采用ANOVA和Tukey事后检验比较生物标志物均值、斜率和截距,并与已建立的阿尔茨海默病指标进行相关分析。
诊断标准与关键数值
- 脑年龄预测模型在留出正常对照数据上测试的平均绝对误差为2.46年。
- 稳定型轻度认知障碍与转化型轻度认知障碍组的BrainAGE在横断面和纵向分析中均有显著差异,最显著的是在转化为阿尔茨海默病前长达4年即可显示显著差异。
临床应用与阅片要点
- BrainAGE可作为单一可解释值总结所有生物标志物,因其考虑疾病的多个维度。
- BrainAGE可用单一值判断受试者呈正常衰老模式还是趋向高风险类别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The prodromal stage of Alzheimer's disease presents an imperative intervention window. This work focuses on using brain age prediction models and biomarkers from FLAIR MR imaging to identify subjects who progress to Alzheimer's disease (converting mild cognitive impairment) or those who remain stable (stable mild cognitive impairment).
MATERIALS AND METHODS: A machine learning model was trained to predict the age of normal control subjects on the basis of volume, intensity, and texture features from 3239 FLAIR MRI volumes. The brain age gap estimation (BrainAGE) was computed as the difference between the predicted and true age, and it was used as a biomarker for both cross-sectional and longitudinal analyses. Differences in biomarker means, slopes, and intercepts were investigated using ANOVA and Tukey post hoc test. Correlation analysis was performed between brain age gap estimation and established Alzheimer's disease indicators.
RESULTS: The brain age prediction model showed accurate results (mean absolute error = 2.46 years) when testing on held out normal control data. The computed BrainAGE metric showed significant differences between the stable mild cognitive impairment and converting mild cognitive impairment groups in cross-sectional and longitudinal analyses, most notably showing significant differences up to 4 years before conversion to Alzheimer's disease. A significant correlation was found between BrainAGE and previously established Alzheimer's disease conversion biomarkers.
CONCLUSIONS: The BrainAGE metric can allow clinicians to consider a single explainable value that summarizes all the biomarkers because it considers many dimensions of disease and can determine whether the subject has normal aging patterns or if he or she is trending into a high-risk category using a single value.
引用
- Crystal O, Maralani PJ, Black S, et al. Brain Age Estimation on a Dementia Cohort Using FLAIR MRI Biomarkers. AJNR Am J Neuroradiol. 2023. PMID: 38050032. doi:10.3174/ajnr.A8059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。